Login to Your Account



Jenrin on ‘Peripherally Selective’ Path to Treat Diabetes

By Marie Powers
Staff Writer

Thursday, September 12, 2013
Virtual biotech Jenrin Discovery LLC spent its first six years targeting peripherally selective (PS) CB1 receptor antagonists as a safer and more effective approach to treat diabetes and other metabolic disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription